NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer's disease in patients who are taking donepezil hydrochloride 10 mg. There is ... About NAMZARIC · Benefits of NAMZARIC · Starting NAMZARIC · Caregiver Support

NAMZARIC (memantine HCl & donepezil HCl) is the only once-a-day capsule for moderate to severe Alzheimer's disease that works in two ways.

NAMZARIC (donepezil hydrochloride; memantine hydrochloride - capsule, extended release;oral) · Manufacturer: ABBVIE Approval date: December 23, 2014. Strength(s): ...

Company: AbbVie Inc. ... Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) is an NMDA receptor antagonist and acetylcholinesterase ...

16 февр. 2015 г. · It was developed by Forest Laboratories in collaboration with Adamas. Forest Labs was later acquired by Actavis. The new drug application (NDA) ...

26 дек. 2014 г. · Actavis and Adamas Announce FDA Approval of Namzaric™, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride.

Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.

NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once ...

We have 36 companies offering NAMZARIC. Get in contact with the supplier of your choice: LGM Pharma · Metrochem API Private Limited ...

7 авг. 2024 г. · Common Brand Name(s): Namzaric ; Common Generic Name(s): memantine/donepezil; memantine HCl/donepezil HCl; memantine hydrochloride/donepezil ...